Expanded Access Program With Nivolumab to Treat Melanoma

NO_LONGER_AVAILABLEEXPANDED_ACCESS
Timeline

Start Date

June 30, 2014

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions
Stage III (Unresectable) or Stage IV Advanced Melanoma
Interventions
DRUG

Nivolumab

Trial Locations (80)

34

Local Institution, Lima

1019

Local Institution, Buenos Aires

1181

Local Institution, Ciudad Autonoma de Buenos Aire

1280

Local Institution, Capital Federal

1426

Local Institution, Caba

1431

Local Institution, Buenos Aires

4000

Local Institution, San Miguel de Tucumán

5000

Local Institution, Córdoba

10029

Icahn School Of Medicine At Mount Sinai, New York

11733

North Shore Hematology/Oncology Associates, P.C., East Setauket

14025

Local Institution, Ribeirão Preto

14780

Local Institution, Barretos

15090

Local Institution, São José do Rio Preto

17210

Local Institution, Jaú

18015

St. Luke'S Hospital, Bethlehem

18103

Lehigh Valley Health Network, Allentown

20057

Local Institution, Washington D.C.

21093

Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Lutherville

30150

Local Institution, Belo Horizonte

30322

Winship Cancer Institute, Atlanta

30380

Local Institution, Belo Horizonte

31404

Summit Cancer Care, Savannah

32256

Cancer Specialists Of North Florida, Jacksonville

32803

Florida Hospital, Orlando

33140

Mount Sinai Comprehensive Cancer Center, Miami Beach

33486

Lynn Cancer Institute At Boca Raton Regional Hospital, Boca Raton

36604

Local Institution, Mobile

36608

Southern Cancer Center Pc, Mobile

37203

Tennessee Oncology, PLLC, Nashville

38138

The Jones Clinic, Pc, Germantown

41950

Local Institution, Salvador

43219

Mid Ohio Oncology/Hematology, Inc,Dba, Columbus

47630

Oncology Hematology Associates Of Sw In, Newburgh

53188

Waukesha Memorial Hospital, Waukesha

60068

Oncology Specialists, S.C., Park Ridge

60130

Local Institution, Fortaleza

68130

Nebraska Cancer Specialists, Omaha

70200

Local Institution, Brasília

86015

Local Institution, Jd. Petropolis-Londrina

88015

Local Institution, Florianópolis

88301

Local Institution, Itajaí

89148

Comprehensive Cancer Centers Of Nevada, Las Vegas

90840

Local Institution, Porto Alegre

92024

Local Institution, Encinitas

98700

Local Institution, Ijuí

99010

Local Institution, Passo Fundo

110221

Local Institution, Bogotá

S2000DSK

Local Institution, Rosario

CPT4000IAK

Local Institution, San Miguel de Tucumán

09060

Local Institution, Santo André

01308

Local Institution, São Paulo

01323

Local Institution, São Paulo

01509

Local Institution, São Paulo

03102

Local Institution, São Paulo

04538

Local Institution, São Paulo

05651

Local Institution, São Paulo

T2N 4N2

Local Institution, Calgary

T6G 1Z2

Local Institution, Edmonton

V1Y 5L3

Local Institution, Kelowna

V7L 2L7

Local Institution, North Vancouver

V5Z 4E6

Local Institution, Vancouver

R3E 0V9

Local Institution, Winnipeg

E1C 8X3

Local Institution, Moncton

A1B 3V6

Local Institution, St. John's

B3H 1V7

Local Institution, Halifax

L8V 5C2

Local Institution, Hamilton

N6A 4L6

Local Institution, London

K1H 8L6

Local Institution, Ottawa

M4N 3M5

Local Institution, Toronto

M5G 2M9

Local Institution, Toronto

H3T 1E2

Local Institution, Montreal

G1R 2J6

Local Institution, Québec

S7N 4H4

Local Institution, Saskatoon

Unknown

Local Institution, Bogotá

Local Institution, Medellín

Local Institution, Santiago de Cali

Local Institution, Lima

Local Institution, Lima

MEDELLIN

Local Institution, Medellín

027

Local Institution, Lima

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02142218 - Expanded Access Program With Nivolumab to Treat Melanoma | Biotech Hunter | Biotech Hunter